Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyfedrine is a small molecule sympathomimetic agent and coronary vasodilator used primarily in the treatment of coronary heart disease, angina pectoris, and acute myocardial infarction. It acts as a partial agonist at β-adrenergic receptors (both β1 and β2), with selectivity over α-adrenergic receptors but can interact with α-receptors at high concentrations. Oxyfedrine improves myocardial metabolism—enabling the heart to better withstand hypoxia—and exerts positive chronotropic and inotropic effects without precipitating angina pectoris. Unlike other vasodilators that may cause the coronary steal phenomenon, oxyfedrine does not worsen angina due to its unique pharmacological profile. Its major active metabolite is norephedrine, which also contributes to its indirectly acting sympathomimetic effects. The drug is chemically unrelated to other antianginal agents[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxyfedrine.